{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:48:20Z","timestamp":1794667700713,"version":"4.9.1"},"reference-count":27,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"32","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2022,11,10]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> High pathologic complete response (pCR) rates and comparably good survival data were seen in a phase II trial combining perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy with trastuzumab for resectable, esophagogastric adenocarcinoma (EGA). The current trial evaluates the addition of trastuzumab and pertuzumab to FLOT as perioperative treatment for human epidermal growth factor receptor 2\u2013positive resectable EGA. <\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p> In this multicenter, randomized phase II\/III trial, patients with human epidermal growth factor receptor 2\u2013positive, resectable EGA (\u2265 clinical tumor 2 or clinical nodal\u2013positive) were assigned to four pre- and postoperative cycles of either FLOT alone (arm A) or combined with trastuzumab and pertuzumab, followed by nine cycles of trastuzumab\/pertuzumab (arm B). The primary end point for the phase II part was the rate of pCR. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> The trial was closed prematurely, without transition into phase III, after results of the JACOB trial were reported. Eighty-one patients were randomly assigned (A: 41\/B: 40) during the phase II part. The pCR rate was significantly improved with the trastuzumab\/pertuzumab treatment (A: 12%\/B: 35%; P = .02). Similarly, the rate of pathologic lymph node negativity was higher with trastuzumab\/pertuzumab (A: 39%\/B: 68%), whereas the R0 resection rate (A: 90%\/B: 93%) and surgical morbidity (A: 43%\/B: 44%) were comparable. Moreover, the inhouse mortality was equal in both arms (overall 2.5%). The median disease-free survival was 26 months in arm A and not yet reached in arm B (hazard ratio, 0.58; P = .14). After a median follow-up of 22 months, the median overall survival was not yet reached (hazard ratio, 0.56; P = .24). Disease-free survival and overall survival rates at 24 months were 54% (95% CI, 38 to 71) and 77% (95% CI, 63 to 90) in arm A and 70% (95% CI, 55 to 85) and 84% (95% CI, 72 to 96) in arm B, respectively. More \u2265 grade 3 adverse events were reported with trastuzumab\/pertuzumab, especially diarrhea (A: 5%\/B: 41%) and leukopenia (A: 13%\/B: 23%). <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> The addition of trastuzumab\/pertuzumab to perioperative FLOT significantly improved pCR and nodal negativity rates at the price of higher rates of diarrhea and leukopenia. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.22.00380","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T19:59:46Z","timestamp":1655409586000},"page":"3750-3761","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":92,"title":["FLOT Versus FLOT\/Trastuzumab\/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2\u2013Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group"],"prefix":"10.1200","volume":"40","clinical-trial-number":[{"clinical-trial-number":"nct02581462","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5972-8504","authenticated-orcid":false,"given":"Ralf-Dieter","family":"Hofheinz","sequence":"first","affiliation":[{"name":"Mannheim Cancer Center, University Hospital Mannheim, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Merx","sequence":"additional","affiliation":[{"name":"Mannheim Cancer Center, University Hospital Mannheim, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg M.","family":"Haag","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Springfeld","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7654-2442","authenticated-orcid":false,"given":"Thomas","family":"Ettrich","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3566-0079","authenticated-orcid":false,"given":"Kersten","family":"Borchert","sequence":"additional","affiliation":[{"name":"Department of Hematology\/ Oncology, Hospital Magdeburg gGmbH, Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Kretzschmar","sequence":"additional","affiliation":[{"name":"Oncology, \u00dcBAG MVZ Mitte, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Teschendorf","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, St.-Josefs-Hospital, Dortmund, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Siegler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 5, Hematology\/ Oncology, Hospital N\u00fcrnberg Nord\/Paracelsus Medical University, N\u00fcrnberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3228-5138","authenticated-orcid":false,"given":"Matthias P.","family":"Ebert","sequence":"additional","affiliation":[{"name":"Mannheim Cancer Center, University Hospital Mannheim, Mannheim, Germany"},{"name":"Medical Department II, Medical Faculty Mannheim, University Heidelberg, Mannheim, Germany"},{"name":"DKFZ-Hector Cancer Institute at the University Medical Center, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eray","family":"Goekkurt","sequence":"additional","affiliation":[{"name":"Hematology-Oncology Practice, Specialist Center Eppendorf, University Cancer Center Hamburg (UCCH), Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Mahlberg","sequence":"additional","affiliation":[{"name":"Medical Department I, Hospital Mutterhaus Trier, Trier, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Homann","sequence":"additional","affiliation":[{"name":"Medical Department II, Hospital Wolfsburg, Wolfsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pink","sequence":"additional","affiliation":[{"name":"Sarcoma Center Berlin-Brandenburg, Helios Hospital Bad Saarow, Bad Saarow, Germany"},{"name":"Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf","family":"Bechstein","sequence":"additional","affiliation":[{"name":"Department of General and Visceral Surgery, Frankfurt University Hospital, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Reichardt","sequence":"additional","affiliation":[{"name":"Sarcoma Center Berlin-Brandenburg, HELIOS Klinikum Berlin Buch, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagen","family":"Flach","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Pius Hospital, University Hospital Oldenburg, Oldenburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6022-073X","authenticated-orcid":false,"given":"Timo","family":"Gaiser","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Medical Faculty Mannheim, University Heidelberg, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Battmann","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Hospital Northwest, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuat S.","family":"Oduncu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Medizinische Klinik und Poliklinik III, University Hospital M\u00fcnchen, M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2319-7734","authenticated-orcid":false,"given":"Maria","family":"Loose","sequence":"additional","affiliation":[{"name":"Institute for Clinical Cancer Research IKF at Hospital Northwest, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disorn","family":"Sookthai","sequence":"additional","affiliation":[{"name":"Institute for Clinical Cancer Research IKF at Hospital Northwest, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pauligk","sequence":"additional","affiliation":[{"name":"Institute for Clinical Cancer Research IKF at Hospital Northwest, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten O.","family":"G\u00f6etze","sequence":"additional","affiliation":[{"name":"Institute for Clinical Cancer Research IKF at Hospital Northwest, Frankfurt am Main, Germany"},{"name":"UCT-University Cancer Center, Hospital Northwest, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah-Eddin","family":"Al-Batran","sequence":"additional","affiliation":[{"name":"Institute for Clinical Cancer Research IKF at Hospital Northwest, Frankfurt am Main, Germany"},{"name":"UCT-University Cancer Center, Hospital Northwest, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321600"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32557-1"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1315406"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33696"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3856"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4597"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30863-0"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01204"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1273201"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11660"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30481-9"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2168.1998.00940.x"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70130-X"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703643"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2007-0204"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1345"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6353"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01814"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00718-X"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.5633"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024649"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70136-0"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30111-0"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz143"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5675-4"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4013"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.22.00380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T23:01:28Z","timestamp":1667862088000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.22.00380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":27,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2022,11,10]]}},"alternative-id":["10.1200\/JCO.22.00380"],"URL":"https:\/\/doi.org\/10.1200\/jco.22.00380","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]},"assertion":[{"value":"2022-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}